Using tasquinimod to improve immunotherapy for brain tumors after surgery
Tasquinimod as an adjunct to immunotherapies administered peri-operatively
This study is looking at how a drug called tasquinimod can help improve treatment for patients with glioblastoma after surgery by reducing inflammation and supporting the immune system when combined with other therapies.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-10928772 on NIH RePORTER |
What this research studies
This research investigates the use of tasquinimod, an anti-inflammatory drug, as a supportive treatment alongside immunotherapies for patients with glioblastoma (GBM) during the critical period after surgery. The study aims to address challenges faced by GBM patients, such as immune suppression from steroids and inflammation caused by surgical procedures, which can hinder the effectiveness of immunotherapy. By targeting the inflammatory response in the brain, the researchers hope to create a more favorable environment for immunotherapy to work effectively. The initial phase of the research will focus on assessing the safety and feasibility of tasquinimod in this context.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who are undergoing surgical treatment and are eligible for immunotherapy.
Not a fit: Patients with glioblastoma who are not undergoing surgery or those who are not candidates for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could enhance the effectiveness of immunotherapy for glioblastoma patients, potentially leading to improved survival rates.
How similar studies have performed: Previous research has shown promise in using anti-inflammatory agents to enhance immunotherapy outcomes, but this specific approach with tasquinimod is novel.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: Portnow, Jana — Beckman Research Institute/city of Hope
- Study coordinator: Portnow, Jana
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.